|Bid||8.50 x 3100|
|Ask||15.00 x 1100|
|Day's Range||13.11 - 13.78|
|52 Week Range||7.67 - 18.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 30, 2018 - Aug 3, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.00|
Lexicon Pharmaceuticals, Inc. (LXRX), today announced that new clinical data for sotagliflozin will be presented at the upcoming 78th American Diabetes Association (ADA) Scientific Sessions in Orlando, FL, from June 22-26. The four accepted abstracts, including one oral presentation and two moderated poster discussions, reflect Lexicon and its collaborator, Sanofi’s efforts to address the unmet need for potential new options for the management of type 1 diabetes.
This morning, WallStEquities.com is focused on the Biotech space, which is engaged in the research and development of new drugs, medical devices, and procedures. The industry includes the manufacturing and marketing of drugs as a result of direct research and development. Under evaluation today are these four equities: Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), MannKind Corp. (NASDAQ: MNKD), Marinus Pharmaceuticals Inc. (NASDAQ: MRNS), and Neptune Technologies & Bioressources Inc. (NASDAQ: NEPT).
A live audio webcast for this conference will be available in the “Investors” section of the Lexicon website at www.lexpharma.com/. Lexicon is a fully integrated biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for patients with serious, chronic conditions. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease.
Label expansion of a few prominent drugs along with pipeline updates were the key areas of focus for investors in the biotech space.
The U.S. Food and Drug Administration (FDA) has accepted Sanofi’s regulatory filing for Zynquista (sotagliflozin). The investigational oral treatment would be used in addition to insulin therapy to improve blood sugar control in adults with type 1 diabetes. “If approved, Zynquista would be the first oral antidiabetic drug approved in the U.S. for use by adults with type 1 diabetes, in combination with insulin,” says Jorge Insuasty, Senior-Vice President, Global Head of Development, Sanofi.
BRIDGEWATER, N.J. and THE WOODLANDS, Texas, May 22, 2018 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has accepted Sanofi's regulatory filing for Zynquista (sotagliflozin). The investigational oral treatment would be used in addition to insulin therapy to improve blood sugar control in adults with type 1 diabetes. "If approved, Zynquista would be the first oral antidiabetic drug approved in the U.S. for use by adults with type 1 diabetes, in combination with insulin." says Jorge Insuasty, Senior-Vice President, Global Head of Development, Sanofi.
NEW YORK, May 11, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of E.W. ...
Gains were broad based as eight out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Immune Design Corp. (NASDAQ: IMDZ), ImmunoCellular Therapeutics Ltd (NYSE AMER: IMUC), La Jolla Pharmaceutical Co. (NASDAQ: LJPC), and Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX).
LONDON, UK / ACCESSWIRE / May 08, 2018 / If you want access to our free research report on Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=LXRX as the Company's latest news hit the wire. On May 04, 2018, the Company announced that new XERMELO® (telotristat ethyl) data from the randomized, double-blind, placebo-controlled Phase-3 TELESTAR study were published in March issue of Clinical Therapeutics. The publication provides the first report of the effects of XERMELO® on changes in weight in patients with neuroendocrine tumors (NETs) and carcinoid syndrome that participated in the Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome (TELESTAR) study.
Significant Dose-Dependent Effects on Changes in Weight Gain and Biochemical and Metabolic Parameters Improvements in Diarrhea Severity and Nutritional Status. THE WOODLANDS, Texas, May 04, 2018-- Lexicon ...
Net Sales of $5.4 Million. Filings Submitted for Regulatory Approval of Sotagliflozin in Type 1 Diabetes. THE WOODLANDS, Texas, May 03, 2018-- Lexicon Pharmaceuticals, Inc., today reported financial results ...
THE WOODLANDS, Texas, May 01, 2018-- Lexicon Pharmaceuticals, Inc. today announced that Lonnel Coats, President and Chief Executive Officer, will present at the following conference:. Bank of America Merrill ...
Lexicon Pharmaceuticals, Inc. (LXRX), will release its first quarter 2018 financial results on Thursday, May 3, 2018 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. EDT (7:00 a.m. CDT) that day to discuss the financial results and to provide a business update.
THE WOODLANDS, Texas, April 03, 2018-- Lexicon Pharmaceuticals, Inc., announced today that it will host its 2018 Research & Development Day on Tuesday, April 10, 2018, from 8:30 a.m. to 11:30 a.m. EDT ...
THE WOODLANDS, Texas, March 29, 2018-- Lexicon Pharmaceuticals, Inc., today announced that the European Medicines Agency has accepted the Marketing Authorization Application filed by Lexicon’ s collaborator, ...
Stock Monitor: Champions Oncology Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 28, 2018 / Active-Investors.com has just released a free research report on Lexicon Pharmaceuticals, Inc. (NASDAQ: ...
New Drug Application Submitted to U.S. Marketing Authorization Application Submitted to European Medicines Agency. THE WOODLANDS, Texas, March 26, 2018-- Lexicon Pharmaceuticals, Inc., today announced ...